Investor Presentation: First Nine Months of 2020
58
Investor presentation
First nine months of 2020
Novo Nordisk obesity pipeline supports efforts to close the
treatment gap
Maturation of innovation
Innovation curve
Body weight set-point and counter regulation.
Weight loss prediction
for patient groups
Oral product
20-30% weight loss
Novo Nordisk's current pipeline is closing the treatment gap
%
0
Normalised
weight
5
10
15
20
Targeted treatment
solutions
25
SaxendaⓇ
10-15% weight loss
30
Today's marketed
treatment options
Semaglutide 2.4 mg
Pipeline
Bariatric surgery
Today
Weight loss over time
1 Long-term Drug Treatment for Obesity: A Systematic and Clinical Review; Susan Z. Yanovski, MD; Jack A. Yanovski, MD, PHD JAMA. 2014; 311(1):74-86. 2 Treatment of Obesity: Weight Loss and Bariatric Surgery; Bruce M. Wolfe, Elizaveta Kvach and Robert H. Eckel;
Circulation Research. 2016; 118:1844-1855
Novo NordiskⓇView entire presentation